Participant flow

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma · Source last updated 2014-10-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients received IV cisplatin 25 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4, gemcitabine 1000 mg/m2 day 1 and solumedrol 250 mg days 1-4 of a 21 day cycle for 6 cycles.

   id

   FG000

   title

   PEGS

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Progression

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Death

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      not protocol specified

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      not eligible

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         34

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         33

      type

      Eligible

   3. achievements

      1. group Id

         FG000

         num Subjects

         33

      type

      Eligible and Began Protocol Therapy

   4. achievements

      1. group Id

         FG000

         num Subjects

         21

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         13

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice